ARID1A Alterations Are Associated with FGFR3-Wild Type, Poor-Prognosis, Urothelial Bladder Tumors

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Balbás Martínez, Cristina ^a   Rodríguez Pinilla, María ^a   Casanova, Ariel ^a   Domínguez, Orlando ^a   Pisano, David G ^a   Gómez, Gonzalo ^a   Lloreta, Josep ^b,c   Lorente, José A ^b   Malats, Núria ^a   Real, Francisco X ^a,c  

^a Structural Biology and Biocomputing Programme   (Spain)

^b HOSPITAL DEL MAR   (Spain)

^c UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN; FIBROBLAST GROWTH FACTOR RECEPTOR 3; RETINOBLASTOMA BINDING PROTEIN 2; ARID1A PROTEIN, HUMAN; FGFR3 PROTEIN, HUMAN; NUCLEAR PROTEIN; PROTEIN P53; TP53 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

AGED; ARID1A GENE; ARTICLE; BLADDER TUMOR; CANCER PROGNOSIS; CANCER STAGING; CARCINOGENESIS; CONTROLLED STUDY; EXON; FEMALE; FGFR3 GENE; GENE CLUSTER; GENE EXPRESSION; GENE INACTIVATION; GENE LOSS; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; PRIMARY TUMOR; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE; UROGENITAL TRACT TUMOR; UROTHELIAL BLADDER TUMOR; WILD TYPE; GENETICS; HEK293 CELL LINE; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MISSENSE MUTATION; MORTALITY; PATHOLOGY; PROGNOSIS; TRANSITIONAL CELL CARCINOMA; TUMOR CELL LINE; UROTHELIUM; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BASE SEQUENCE; CARCINOMA, TRANSITIONAL CELL; CELL LINE, TUMOR; DNA MUTATIONAL ANALYSIS; FEMALE; HEK293 CELLS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MUTATION, MISSENSE; NUCLEAR PROTEINS; PROGNOSIS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 84877075335     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062483     Document Type: Article

References (55)

1. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, et al. (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49: 466-475.
2. Thomas F, Rosario DJ, Rubin N, Goepel JR, Abbod MF, et al. (2012) The long-term outcome of treated high-risk nonmuscle-invasive bladder cancer: Time to change treatment paradigm? Cancer; doi: 10.1002/cncr.27587. [Epub ahead of print] PubMed PMID: 22544645.
3. Wu XR, (2005) Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer 5: 713-725.
4. Luis NM, López-Knowles E, Real FX, (2007) Molecular biology of bladder cancer. Clin Transl Oncol 9: 5-12.
5. Cappellen D, De Oliveira C, Ricol D, de Medina S, Bourdin J, et al. (1999) Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 23: 18-20.
6. Bakkar AA, Wallerand H, Radvanyi F, Lahaye JB, Pissard S, et al. (2003) FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res 63: 8108-8112.
7. Hernández S, López-Knowles E, Lloreta J, Kogevinas M, Amorós A, et al. (2006) Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol 24: 3664-3671.
8. van Rhijn BW, van der Kwast TH, Liu L, Fleshner NE, Bostrom PJ, et al. (2012) The FGFR3 mutation is related to favorable pT1 bladder cancer. J Urol 187: 310-314.
9. López-Knowles E, Hernández S, Malats N, Kogevinas M, Lloreta J, et al. (2006) PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. Cancer Res 66: 7401-7404.
10. Jebar AH, Hurst CD, Tomlinson DC, Johnston C, Taylor CF, et al. (2005) FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene 24: 5218-5225.
11. Wong KM, Hudson TJ, McPherson JD, (2011) Unraveling the genetics of cancer: genome sequencing and beyond. Annu Rev Genomics Hum Genet 12: 407-430.
12. Zhang J, Baran J, Cros A, Guberman JM, Haider S, et al. (2011) International Cancer Genome Consortium Data Portal-a one-stop shop for cancer genomics data. Database (Oxford) bar026.
13. Lindgren D, Sjödahl G, Lauss M, Staaf J, Chebil G, et al. (2012) Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma. PLoS One 7: e38863.
14. Gui Y, Guo G, Huang Y, Hu X, Tang A, et al. (2011) Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet 43: 875-878.
15. García-Closas M, Malats N, Silverman D, Dosemeci M, Kogevinas M, et al. (2005) NAT2 slow acetylation and GSTM1 null genotypes increase bladder cancer risk: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 366: 649-659.
16. Guey LT, García-Closas M, Murta-Nascimento C, Lloreta J, Palencia L, et al. (2010) Genetic susceptibility to distinct bladder cancer subphenotypes. Eur Urol 57: 283-292.
17. Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, et al. (2010) ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 363: 1532-1543.
18. Hernandez S, Lopez-Knowles E, Lloreta J, Kogevinas M, Jaramillo R, et al. (2005) FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis. Clin Cancer Res 11: 5444-5450.
19. Hafner C, van Oers JM, Vogt T, Landthaler M, Stoehr R, et al. (2006) Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi. J Clin Invest 116: 2201-2207.
20. Fujita PA, Rhead B, Zweig AS, Hinrichs AS, Karolchik D, et al. (2010) The UCSC Genome Browser database: update 2011. Nucleic Acids Res 39: D876-D882.
21. Kumar P, Henikoff S, Ng PC, (2009) Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 4: 1073-1081.
22. Dyrskjøt L, Thykjaer T, Kruhøffer M, Jensen JL, Marcussen N, et al. (2003) Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet 33: 90-96.
23. Sjödahl G, Lauss M, Lövgren K, Chebil G, Gudjonsson S, et al. (2012) A molecular taxonomy for urothelial carcinoma. Clin Cancer Res 18: 3377-3386.
24. Amaral AFS, Méndez-Pertuz M, Muñoz A, Silverman DT, Allory Y, et al. (2012) Plasma 25-hydroxyvitamin D3 levels and bladder cancer risk according to tumor stage and FGFR3 status: a mechanism-based epidemiological study. J Natl Cancer Inst 104: 1897-1904.
25. López-Knowles E, Hernández S, Kogevinas M, Lloreta J, Amorós A, et al. (2006) The p53 pathway and outcome among patients with T1G3 bladder tumors. Clin Cancer Res 12: 6029-6036.
26. Masters JR, Hepburn PJ, Walker L, Highman WJ, Trejdosiewicz LK, et al. (1986) Tissue culture model of transitional cell carcinoma: characterization of twenty-two human urothelial cell lines. Cancer Res 46: 3630-3636.
27. Lin CW, Lin JC, Prout GR, (1985) Establishment and characterization of four human bladder tumor cell lines and sublines with different degrees of malignancy. Cancer Res 45: 5070-5079.
28. Sabichi A, Keyhani A, Tanaka N, Delacerda J, Lee IL, et al. (2006) Characterization of a panel of cell lines derived from urothelial neoplasms: genetic alterations, growth in vivo and the relationship of adenoviral mediated gene transfer to coxsackie adenovirus receptor expression. J Urol 175: 1133-1137.
29. Jones S, Wang TL, Shih IeM, Mao TL, Nakayama K, et al. (2010) Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 330: 228-231.
30. Jones S, Li M, Parsons DW, Zhang X, Wesseling J, et al. (2012) Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Hum Mutat 33: 100-103.
31. Guan B, Mao TL, Panuganti PK, Kuhn E, Kurman RJ, et al. (2011) Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma. Am J Surg Pathol 35: 625-632.
32. Wilson BG, Roberts CW, (2011) SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer 11: 481-492.
33. Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, et al. (2012) Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet 44: 694-698.
34. Tomlinson DC, Baldo O, Harnden P, Knowles MA, (2007) FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J Pathol 213: 91-98.
35. Malats N, Bustos A, Nascimento CM, Fernandez F, Rivas M, et al. (2005) P53 as a prognostic marker for bladder cancer: A meta-analysis and review. Lancet Oncol 6: 678-686.
36. Real FX, (2007) p53: it has it all, but will it make to the clinic as a marker in bladder cancer? J Clin Oncol 25: 5341-5344.
37. Volkmer JP, Sahoo D, Chin RK, Ho PL, Tang C, et al. (2012) Three differentiation states risk-stratify bladder cancer into distinct subtypes. Proc Natl Acad Sci USA 109: 2078-2083.
38. Rieger KM, Little AR, Swart JM, Kastrinakis WV, Fitzgerald JM, et al. (1995) Human bladder carcinoma cell lines as indicators of oncogenic change relevant to urothelial neoplastic progression. Br J Cancer 72: 683-690.
39. Cancer Genome Atlas Network, (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature 487: 330-337.
40. Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, et al. (2012) Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150: 1107-1120.
41. Love C, Sun Z, Jima D, Li G, Zhang J, et al. (2012) The genetic landscape of mutations in Burkitt lymphoma. Nat Genet44: 1321-1325.
42. Mamo A, Cavallone L, Tuzmen S, Chabot C, Ferrario C, et al. (2012) An integrated genomic approach identifies ARID1A as a candidate tumor-suppressor gene in breast cancer. Oncogene 31: 2090-2100.
43. Zhang X, Sun Q, Shan M, Niu M, Liu T, et al. (2013) Promoter Hypermethylation of ARID1A Gene Is Responsible for Its Low mRNA Expression in Many Invasive Breast Cancers. PLoS One 8: e53931.
44. Huang J, Deng Q, Wang Q, Li KY, Dai JH, et al. (2012) Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma. Nat Genet 44: 1117-1121.
45. Iyer G, Hanrahan AJ, Milowsky MI, Al-Ahmadie H, Scott SN, et al. (2012) Genome sequencing identifies a basis for everolimus sensitivity. Science 338: 221.
46. Wang K, Kan J, Yuen ST, Shi ST, Chu KM, et al. (2011) Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet 43: 1219-1223.
47. Yamamoto S, Tsuda H, Takano M, Tamai S, Matsubara O, (2012) Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations. Mod Pathol 25: 615-624.
48. Yamamoto S, Tsuda H, Takano M, Tamai S, Matsubara O, (2012) PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma. Virchows Arch 460: 77-87.
49. Deem AK, Li X, Tyler JK, (2012) Epigenetic regulation of genomic integrity. Chromosoma 121: 131-151.
50. Romero OA, Setien F, John S, Gimenez-Xavier P, Gómez-López G, et al. (2012) The tumour suppressor and chromatin-remodelling factor BRG1 antagonizes Myc activity and promotes cell differentiation in human cancer. EMBO Mol Med 4: 603-616.
51. Vallot C, Stransky N, Bernard-Pierrot I, Hérault A, Zucman-Rossi J, et al. (2011) A novel epigenetic phenotype associated with the most aggressive pathway of bladder tumor progression. J Natl Cancer Inst 103: 47-60.
52. Guan B, Wang TL, ShihIe M, (2011) ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res 71: 6718-6727.
53. Birnbaum DJ, Adélaïde J, Mamessier E, Finetti P, Lagarde A, et al. (2011) Genome profiling of pancreatic adenocarcinoma. Genes Chromosomes Cancer 50: 456-465.
54. Shain AH, Giacomini CP, Matsukuma K, Karikari CA, Bashyam MD, et al. (2012) Convergent structural alterations define SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeler as a central tumor suppressive complex in pancreatic cancer. Proc Natl Acad Sci USA 109: E252-259.
55. Gao X, Tate P, Hu P, Tjian R, Skarnes WC, et al. (2008) ES cell pluripotency and germ-layer formation require the SWI/SNF chromatin remodeling component BAF250a. Proc Natl Acad Sci USA 105: 6656-6661.